Skip to main content
Journal ArticleOPEN ACCESS

Rifampicin Bioavailability in Fixed-Dose Combinations for Tuberculosis Treatment: Evidence and Policy Actions

  • Sadaphal P
  • Chakraborty K
  • Jassim-AlMossawi H
  • et al.
Journal of Lung Health and Diseases (2019) 3(3) 9-15
DOI: 10.29245/2689-999x/2019/3.1155
N/ACitations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

… that combining anti-tuberculosis drugs into single formulations does not change their … consequences resulting from suboptimal quality of medication. The authors acknowledge that this …

Cite

CITATION STYLE

APA

Sadaphal, P., Chakraborty, K., Jassim-AlMossawi, H., Pillay, Y., Roscigno, G., Kaul, A., … DeStefano, A. (2019). Rifampicin Bioavailability in Fixed-Dose Combinations for Tuberculosis Treatment: Evidence and Policy Actions. Journal of Lung Health and Diseases, 3(3), 9–15. https://doi.org/10.29245/2689-999x/2019/3.1155

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free